The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Optimizing Patient Access to CDK 4/6 Inhibitors in the Armamentarium Against Metastatic Breast Cancer
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
The availability of CDK 4/6 inhibitors (CDK 4/6i) in combination with an aromatase inhibitor (AI) in HR+/HER2- Metastatic Breast Cancer (mBC) has led to additional months or years of progression free survival (PFS) for patients vs. an AI alone.
The goal is to close gaps in care so that all HR+/HER2- mBC patients have equal access to this therapeutic option. All patients should have access to the same high quality of care as delivered by academic or NCI-designated cancer centers.
The intent of this RFP is to increase healthcare professionals’ knowledge and understanding of the clinical trial and real world evidence for the CDK 4/6i class.
Independent education proposals should include a plan for providing information on clinical trial design and results, real-world study design and results, real-world clinical experience, and best-practices in the treatment of HR+/HER2- mBC.
The education should enable both clinical and access decision makers to better analyze, evaluate the quality of, and interpret relevant findings from randomized clinical trials and real world studies of CDK 4/6i, in terms of thevalidity, design, and source so that they can accurately interpret current evidentiary findings and incorporate this knowledge into their daily practice and decision making.
Grant Application Due Date: September 27, 2021
Areas of Interest
The two audiences of interest for this RFP are as follows. Proposals may address one or both of these groups.
1) Medical oncologists and the cancer care team in community settings including rural and underserved locations.
2) Institutional decision-makers such as managed-care professionals, pharmacy-managers, clinical pathway implementors, organized medicine leaders etc.
All activity formats will be considered under this RFP (live in-person, live virtual, enduring courses and materials, innovative technologies & platforms etc.) Ongoing or continuous learning experiences are also in-scope such as the “telementoring” all-teach all-learn approach of Project ECHO from the University of New Mexico.
Geographic Scope: • United States
• The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. • If the project involves multiple departments within an institution and / or between different institutions / organizations / associations all institutions must have a relevant role, and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited.
Individual projects requesting up to $250,000 will be considered. Please note, smaller grant request amounts are strongly encouraged. The estimated total available budget related to this RFP is $800,000.